EUVIMEDEUVIMED entdecken
Systematische ÜbersichtVergleichsstudieMetaanalyseOpen Access · CC BY-NC 4.0

Allogeneic versus autologous stem cell transplantation after relapsing following first line autologous transplantation for multiple myeloma: A systematic review

Heinz Ludwig iD, Sarah Bernhard, Takashi Ikeda, Cesar O Freytes, Martin Schreder, Koji Kawamura, Yoshiko Atsuta, Hiroyuki Takamatsu iD, David H Vesole, Parameswaran Hari, Julie Krainer, Axel Hinke

Cancer · 2025

DOI: 10.1002/cncr.35896 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cancer, 2025. Verfasst von Heinz Ludwig und 11 weiteren Autor:innen. Beteiligte Einrichtung: Wilhelminen Cancer Research Institute, Vienna, Austria. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Transplantation, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Austrian Forum Against Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Allogeneic stem cell transplantation (allo‐SCT) has curative potential and was previously considered by several experts superior to autologous stem cell transplantation (auto‐SCT) for patients with multiple myeloma relapsing after first‐line auto‐SCT.

Methods

The authors conducted a comprehensive literature review of English‐language studies published from 1995 to October 2024. Five studies comparing allo‐SCT with second auto‐SCT following first line auto‐SCT in multiple myeloma were included. Two additional studies comparing patients with or without a suitable allo‐SCT donor after relapse were analyzed separately. Individual data from 815 patients were obtained from two large databases: the Japan Society for Hematopoietic Stem Cell Transplantation and the Center for International Blood & Marrow Transplant Research (CIBMTR). Data from five smaller studies (three comparing allo‐vs. auto‐SCT and two comparing donor vs. no‐donor groups) presented via Kaplan–Meier curves were digitized using the Shiny app. Meta‐analyses were performed using R 4.3.3. Kaplan–Meier and log‐rank tests for overall survival (OS) and progression‐free survival (PFS) were conducted in SPSS.

Results

Individual patient data analysis showed significantly longer OS in the auto‐SCT group. This benefit was consistent in the three smaller studies. PFS was also superior for auto‐SCT in the CIBMTR data set and the pooled smaller studies. In the two‐donor vs. no‐donor studies, the donor group showed better PFS, with OS also improved when data were combined.

Conclusions

Allo‐SCT after relapse from first line auto‐SCT resulted in inferior OS and PFS compared to a second auto‐SCT. These findings indicate that allo‐SCT should no longer be recommended in patients with multiple myeloma relapsing after first line auto‐SCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHematopoietic Stem Cell TransplantationNeoplasm Recurrence, LocalHumansTransplantation, AutologousTransplantation, HomologousRecurrence

Stichwörter der Autor:innen

allogeneic stem cell transplantationautologous stem cell transplantationmultiple myelomarelapsed/refractory myelomasecond‐line therapy

Autor:innen und Institutionen

  • Wilhelminen Cancer Research Institute, Vienna, Austria.
  • Division of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center, Shizuoka, Japan.
  • University of Texas Health Science Center San Antonio, San Antonio, Texas, USA.
  • Department of Medicine I, Center for Oncology and Hematology, Clinic Ottakring, Vienna, Austria.
  • Hematology, Tottori University Hospital, Yonago, Japan.
  • Japanese Data Center For Hematopoietic Cell Transplantation, Nagakute, Japan.

ORCID-Profile: Heinz Ludwig, Hiroyuki Takamatsu

Förderung

  • Austrian Forum Against Cancer

Zitieren

APA

Ludwig, H., Bernhard, S., Ikeda, T., Freytes, C. O., Schreder, M., Kawamura, K., Atsuta, Y., Takamatsu, H., Vesole, D. H., Hari, P., Krainer, J., & Hinke, A. (2025). Allogeneic versus autologous stem cell transplantation after relapsing following first line autologous transplantation for multiple myeloma: A systematic review. Cancer. https://doi.org/10.1002/cncr.35896

Vancouver

Ludwig H, Bernhard S, Ikeda T, Freytes CO, Schreder M, Kawamura K, et al. Allogeneic versus autologous stem cell transplantation after relapsing following first line autologous transplantation for multiple myeloma: A systematic review. Cancer. 2025. doi:10.1002/cncr.35896

BibTeX
@article{Ludwig2025,
  author = {Ludwig, Heinz and Bernhard, Sarah and Ikeda, Takashi and Freytes, Cesar O and Schreder, Martin and Kawamura, Koji and Atsuta, Yoshiko and Takamatsu, Hiroyuki and Vesole, David H and Hari, Parameswaran and Krainer, Julie and Hinke, Axel},
  title = {Allogeneic versus autologous stem cell transplantation after relapsing following first line autologous transplantation for multiple myeloma: A systematic review},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35896}
}
Kostenlos starten →